Cite
HARVARD Citation
Conte, P. et al. (n.d.). 191PD_PR9 weeks versus 1 year adjuvant trastuzumab for HER2+ early breast cancer: Subgroup analysis of the ShortHER trial allows to identify patients for whom a shorter trastuzumab administration may have a favourable risk/benefit ratio. Annals of oncology. p. . [Online].